menu ☰
menu ˟

P2-307: CPHPC depletes serum amyloid P component from the cerebrospinal fluid in Alzheimer's disease



Topic: Chronic Conditions
Back pain
Type: Report
Region: Republic of Ireland

UCL Institute of Neurology, London, United KingdomCentre for Amyloidosis and Acute Phase Proteins, University College London, London, United Kingdom.This was a small, unblinded case series looking at the safety of the drug CPHPC in people with Alzheimer’s disease, and its effects on the levels of the SAP protein in the fluid surrounding the brain and spinal cord (cerebrospinal fluid).SAP is known to bind to and stabilise amyloid fibrils (tangles), which form the typical type of deposits found in the brains of people with Alzheimer’s. SAP is found in the cerebrospinal fluid, amyloid deposits and typical protein tangles found in the nerve cells in the brains of people with Alzheimer’s disease.The researchers thought that SAP could be playing a role in the degeneration of the nerves that occurs in Alzheimer’s, and that by stopping it from binding to amyloid tangles it might affect the progression of the disease. The drug CPHPC was developed to stop SAP binding to amyloid tangles and remove it where it had already bound.The researchers enrolled five patients aged 53 to 67 years old with mild-to-moderate probable Alzheimer’s disease. Details of how the disease was diagnosed were not reported in the paper.The researchers injected 60 milligrams (mg) of CPHPC under the skin of these patients three times a day for 12 weeks. They measured the concentration of SAP in the cerebrospinal fluid of the patients before CPHPC treatment, every four weeks during treatment, and four weeks after treatment had finished.The researchers also measured the levels of CPHPC and other chemicals in blood and cerebrospinal fluid during the study.At the start and end of the study, patients had MRI brain scans and had their cognitive abilities measured using standard tests called the MMSE, ADAS-Cog and CIBIC+. The researchers also assessed whether the patients experienced any adverse effects of the drug treatment.The researchers carried out further experiments looking at how CPHPC interacts with SAP in solutions, and how the compounds formed behave when injected into mice.



Rights: Public
Suggested citation:

PNAS. (2009) P2-307: CPHPC depletes serum amyloid P component from the cerebrospinal fluid in Alzheimer's disease [Online]. Available from: [Accessed: 31st March 2020].


View your saved citations and reading lists


Click here to view all the resources gathered from this organisation's website.